细胞松弛素B通过激动Nur77-血栓调节蛋白通路改善脓毒症高凝状态
本研究在盲肠结扎穿刺(CLP)脓毒症诱导凝血病(SIC)小鼠模型中,观察细胞松弛素B(Csn-B)上调Nur77对高凝状态的作用。结果显示Csn-B依赖血管内皮Nur77激活血栓调节蛋白-活化蛋白C系统、恢复纤溶稳态并抑制补体C3和C5激活,从而改善SIC早期凝血病。
要点
- 脓毒症诱导血管内皮细胞Nur77上调,内皮Nur77敲除加重器官损伤和早期凝血功能障碍。
- Csn-B减轻肿瘤坏死因子α刺激的人脐静脉内皮细胞促凝反应,该作用依赖Nur77-血栓调节蛋白通路激活。
- Csn-B依赖血管内皮Nur77抑制凝血因子升高、增强血栓调节蛋白-活化蛋白C、恢复纤溶稳态并抑制C3和C5激活。
核心结论
- Csn-B通过上调血管内皮Nur77增加内源性血栓调节蛋白,改善脓毒症早期凝血病。
研究设计与样本
- 采用盲肠结扎穿刺(CLP)操作制备SIC小鼠模型。
- CLP后5小时检测凝血相关指标及肝、肺、肾组织病理损伤。
- 观察Csn-B对转染Nur77或血栓调节蛋白小干扰RNA的人脐静脉内皮细胞在肿瘤坏死因子α刺激下凝血时间的影响。
- 在血管内皮条件性敲除Nur77小鼠CLP后观察Csn-B对生存、器官损伤、微血栓、凝血因子、血栓调节蛋白-活化蛋白C抗凝系统、纤溶系统和补体系统的影响。
主要发现
- 脓毒症诱导血管内皮细胞Nur77上调。
- 血管内皮Nur77敲除加重脓毒症器官损伤和早期凝血功能障碍。
- Csn-B减轻肿瘤坏死因子α刺激的人脐静脉内皮细胞促凝反应,该作用依赖Nur77-血栓调节蛋白通路激活。
- Csn-B依赖血管内皮Nur77激活抑制凝血因子升高、增强血栓调节蛋白-活化蛋白C激活、恢复纤溶稳态并抑制C3和C5激活,从而改善SIC高凝状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sepsis-induced coagulopathy (SIC) is often a sign of high mortality and poor prognosis in patients with sepsis. Thrombomodulin (TM) plays an important anticoagulant role by activating protein (AP)C. OBJECTIVES: Our previous study has shown that the overexpression of Nur77 upregulates TM expression in human umbilical vein endothelial cells (HUVECs). This study aimed to investigate whether upregulation of Nur77 using cytosporone (Csn)-B could ameliorate SIC. METHODS: A mouse model of SIC was prepared by cecum ligation and puncture (CLP) operation. Five hours after CLP, coagulation-related indicators and histopathologic injury of the liver, lungs, and kidneys were investigated. The effect of Csn-B on the clotting time of HUVECs transfected with Nur77 or TM small-interfering RNA in response to tumor necrosis factor α stimulation was observed. The effects of Csn-B on survival, organ damage, microthrombosis, coagulation factors, TM activated protein C anticoagulant system, fibrinolytic system, and complement system were observed in vascular endothelial conditional knockout Nur77 mice after CLP. RESULTS: Sepsis-induced upregulation of Nur77 in vascular endothelial cells. Knockout of Nur77 in vascular endothelium exacerbated organ damage and early coagulation dysfunction in sepsis. Csn-B attenuated the procoagulant response of HUVEC to tumor necrosis factor α stimulation, which is dependent on the activation of Nur77-TM pathway. Furthermore, Csn-B relied on activation of vascular endothelial Nur77 to inhibit the increase of coagulation factors, enhance activation of TM activated protein C, restore fibrinolysis homeostasis, and inhibit C3 and C5 activation to ameliorate hypercoagulability in SIC. CONCLUSION: Csn-B improves early coagulopathy in sepsis by increasing endogenous TM through upregulating Nur77 in the vascular endothelium.
引用
- Lu X, Chen L, Tu Y, et al. Cytosporone B ameliorates hypercoagulability in sepsis by agonizing the Nur77-thrombomodulin pathway. J Thromb Haemost. 2025. PMID: 41177456. doi:10.1016/j.jtha.2025.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。